Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. It is active against many Gram-positive, Gram-negative, and anaerobic bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin-structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (as empiric therapy) ## Adult Dosing Standard dose: 3.375 grams (3g piperacillin/0.375g tazobactam) IV every 6 hours. Higher dose for severe infections or specific pathogens: 4.5 grams (4g piperacillin/0.5g tazobactam) IV every 6 or 8 hours. Maximum daily dose: Generally not to exceed 18 grams (16g piperacillin/2g tazobactam) in 24 hours, though specific institutional protocols may vary. Duration of therapy is typically 7-14 days, depending on the infection and clinical response. ## Pediatric Dosing For patients 2 months and older: Dosing is based on the piperacillin component. * Uncomplicated infections: 90-100 mg piperacillin/kg/day IV divided every 6 or 8 hours. * Complicated infections: 200-300 mg piperacillin/kg/day IV divided every 6 or 8 hours. Maximum pediatric dose: Generally 18 grams per day (or 4.5 grams per dose). Consult specific pediatric guidelines for precise dosing based on indication and weight. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No dose adjustment. * CrCl 20-40 mL/min: Administer usual dose every 8 hours. * CrCl < 20 mL/min: Administer usual dose every 12 hours. * Hemodialysis: Administer usual dose every 8 hours and supplement with one additional dose of the same size after each dialysis session. * **Hepatic Impairment:** No specific dose adjustment recommended, but caution advised. ## Contraindications * Known severe hypersensitivity to piperacillin, tazobactam, other penicillins, or cephalosporins. * History of cholestatic jaundice or hepatic dysfunction associated with piperacillin/tazobactam. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures (especially with high doses or renal impairment), hematologic abnormalities (neutropenia, thrombocytopenia, anemia), liver enzyme elevations. ## Key Drug Interactions * **Probenecid:** May increase and prolong serum concentrations of piperacillin/tazobactam. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Warfarin:** Piperacillin may decrease warfarin's anticoagulant effect. Monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance, increasing its toxicity. * **Tetracyclines, chloramphenicol, aminoglycosides:** May antagonize the bactericidal effect of penicillins. Avoid concurrent use if possible, or monitor for effectiveness. ## Monitoring * Renal function (creatinine, BUN) for dose adjustments. * Liver function tests (LFTs) periodically, especially with prolonged therapy. * Complete blood count (CBC) for hematologic abnormalities. * Signs and symptoms of infection for efficacy. * Signs and symptoms of hypersensitivity reactions. * Stool for *C. difficile* if diarrhea develops. ## Clinical Pearls * Piperacillin/tazobactam covers *Pseudomonas aeruginosa*. * Reconstituted solution is stable for 24 hours at room temperature and 7 days when refrigerated. * Administer IV infusion over at least 30 minutes. Rapid infusion can increase the risk of hypersensitivity reactions. * The beta-lactamase inhibitor tazobactam broadens the spectrum of piperacillin to include many beta-lactamase-producing bacteria. *** *Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult the most current prescribing information and institutional guidelines for definitive drug management.*